相关实验视频

Updated: Jul 7, 2025

Early Detection of Drug-Induced Renal Hemodynamic Dysfunction Using Sonographic Technology in Rats

Early Detection of Drug-Induced Renal Hemodynamic Dysfunction Using Sonographic Technology in Rats

Published on: March 11, 2016

肝综合征 - - 对诊断和治疗的新见解

Krzysztof Badura¹, Weronika Frąk¹, Joanna Hajdys¹

¹Department of Nephrocardiology, Medical University of Lodz, Ul. Zeromskiego 113, 90-549 Lodz, Poland.

International journal of molecular sciences

|December 23, 2023

概括

肝硬化综合征 (HRS),肝硬化患者的脏问题,越来越多地通过新的生物标志物和机制来理解. 研究推进了管理策略,包括新型疗法,以改善患者的治疗结果.

科学领域:

胃肠病学和肝病学
腎臟病學 (nephrology) 是一種醫學專業.
临界护理医学临界护理医学

背景情况:

肝硬化综合征 (HRS) 是肝硬化的严重并发症,其特征是功能障碍.
它是急性损伤的主要原因,构成重大公共卫生挑战.
门高血压是HRS的主要潜在原因.

研究的目的:

审查导致HRS的病理生理机制.
总结目前和新兴的HRS管理策略.
突出了解和诊断HRS.最近的进展.

主要方法:

关于病理生理机制的文献综述.
分析诊断方面的进展,包括生物标志物.
治疗干预措施和新型治疗方法的总结.

主要成果:

确定的主要病理生理路径包括循环功能障碍,细菌感染,炎症和自身调节受损.
损伤的新生物标志物正在帮助HRS诊断.
目前的治疗包括血管收缩药物,脏替代疗法和肝移植.

结论:

了解HRS复杂的病理生理学对于制定有效的预防和治疗策略至关重要.
正在进行的新疗法研究有望改善HRS患者的治疗结果.
结合医疗管理和移植的综合方法至关重要.

关键词:

急性脏损伤急性脏损伤生物标志物生物标志物肝硬化是肝硬化的一种疾病.肝发性综合征肝发性综合征肝移植肝移植肝移植新型疗法新型疗法病理生理学病理生理学血管收缩药物是一种药物.

更多相关视频

5/6 Nephrectomy Using Sharp Bipolectomy Via Midline Laparotomy in Rats

5/6 Nephrectomy Using Sharp Bipolectomy Via Midline Laparotomy in Rats

Published on: April 4, 2025

Improved Renal Denervation Mitigated Hypertension Induced by Angiotensin II Infusion

Improved Renal Denervation Mitigated Hypertension Induced by Angiotensin II Infusion

Published on: May 26, 2022

相关概念视频

Renal Failure: Dose Adjustments

Renal Failure: Dose Adjustments

In patients with renal impairment, drugs undergo significant changes in their pharmacokinetics, which require dosage adjustments to ensure safe and effective therapy.
Reduced renal clearance and elimination rate are common outcomes of renal impairment. These alterations lead to a prolonged elimination half-life and an altered apparent volume of distribution for drugs. As a result, dosage adjustments are typically necessary to maintain optimal drug levels in the body.
However, dosage adjustments...

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...